Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
17 oct. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
17 oct. 2023 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 août 2023 07h15 HE
|
Monte Rosa Therapeutics, Inc.
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug...
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
26 juil. 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
30 mai 2023 16h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
23 mai 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression in autoimmunity models, supporting potential applications across multiple...
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 mai 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023Cash runway into 2025 supports operations and advancement of pipeline of...
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
17 avr. 2023 16h30 HE
|
Monte Rosa Therapeutics, Inc.
Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in MYC-driven tumor cellsPhase 1/2 clinical trial of MRT-2359 ongoing in...
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
23 mars 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
16 mars 2023 07h30 HE
|
Monte Rosa Therapeutics, Inc.
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast...